Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 105358, 11 pages
Research Article

Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach

1Department of Biochemistry, Faculty of Science, Mahidol University, 272 Rama VI Road, Phayathai, Rajdhevi, Bangkok 10400, Thailand
2Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand
3Proteomics Research Laboratory, Genome Institute, National Center for Genetic Engineering and Biotechnology, NSTDA, Pathumthani 12120, Thailand

Received 20 August 2014; Accepted 13 October 2014

Academic Editor: Joy Scaria

Copyright © 2015 Tavan Janvilisri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Aim. Cholangiocarcinoma (CCA) is the most frequent biliary malignancy, which poses high mortality rate due to lack of early detection. Hence, most CCA cases are present at the advanced to late stages with local or distant metastasis at the time of diagnosis. Currently available tumor markers including CA19-9 and CEA are inefficient and of limited usage due to low sensitivity and specificity. Here, we attempt to identify serum tumor markers for CCA that can effectively distinguish CCA from benign biliary tract diseases (BBTDs). Methods. Serum samples from 19 CCA patients and 17 BBTDs were separated by SDS-PAGE followed with LC-MS/MS and were subjected to statistical analysis and cross-validation to identify proteins whose abundance was significantly elevated or suppressed in CCA samples compared to BBTDs. Results. In addition to identifying several proteins previously known to be differentially expressed in CCA and BBTDs, we also discovered a number of molecules that were previously not associated with CCA. These included FAM19A5, MAGED4B, KIAA0321, RBAK, and UPF3B. Conclusions. Novel serum biomarkers to distinguish CCA from BBTDs were identified using a proteomic approach. Further validation of these proteins has the potential to provide a biomarker for differentiating CCA from BBTDs.